del Zoppo G J
Department of Molecular and Experimental Medicine, Scripps Research Institute, La Jolla, CA 92037, USA.
Thromb Haemost. 1997 Jul;78(1):183-90.
Following the initial report of the clinical use of plasminogen activators (PAs) in cerebrovascular thrombosis in 1958, interest in the efficacy of this approach accelerated only when the need for acute intervention in stroke was recognized. The use of PAs in acute ischemic stroke is based on the observation that approximately 80-90% of focal cerebral ischemic events presenting as strokes within 8 hr of symptom onset are due to atherothrombotic and embolic occlusions.
1958年首次报道纤溶酶原激活剂（PAs）在脑血管血栓形成中的临床应用后，只有当人们认识到中风需要急性干预时，对这种方法疗效的兴趣才加速增长。急性缺血性中风中使用PAs是基于以下观察结果：在症状出现后8小时内表现为中风的局灶性脑缺血事件中，约80-90%是由动脉粥样硬化血栓形成和栓塞性闭塞引起的。
